NCT01181986View on ClinicalTrials.gov

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Exenatide SC

Exenatide 5-10 ug sc BID/10 days

DRUG

Exenatide IV

50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days

DRUG

Placebo SC

Placebo sc BID/10days

DRUG

Exendin-9

Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.

DRUG

Placebo IV

Intravenous infusion for 45 minutes on 1 out of 3 visits

Trial Locations (1)

85012

Phoenix VA Medical Center, Phoenix

Sponsors
All Listed Sponsors
collaborator

American Diabetes Association

OTHER

collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

Carl T. Hayden VA Medical Center

FED